Mary Rozenman is an architect of life sciences company creation, capital formation, and partnering and has devoted her career to the advancement of new therapeutics and transformative technologies to better patient lives. Since 2019, Mary has served as CFO/CBO of insitro, which is bringing new and better medicines, faster, to the patients who can benefit most through the power of machine learning and data at scale. Backed by more than $700 million in capital, insitro is unlocking new disease insights and de-risking target and therapeutic hypotheses to build a “pipeline through platform” in three therape...read more